Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
174
resultados
Última actualización
02/11/2025 [06:51:00]
Resultados 75 a 100 de 174
Resumen de: MX2025007398A
The present invention provides, in part, bis-ester and amide cationic lipid compounds of Formula (I):, or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (II):, or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (III):, or a pharmaceutically acceptable salt thereof, and bis-ester and amide cationic lipid compounds of Formula (IV):, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Resumen de: WO2024133892A1
A crosslinked vesicle comprising an outer layer and an inner core, said outer layer comprising a cationic amphiphilic peptide and said inner core comprising a fluorinated compound in liquid form, wherein said cationic amphiphilic peptide is a compound of formula (I) HB - CL - HP (I), wherein HB is a fluorinated hydrophobic block, CL is a cross-linking motif, HP is a cationic hydrophilic amino acid sequence having an alpha-helix structure and comprising at least (1) positive charge and said vesicle has a zeta potential of at least (20) mV.
Resumen de: CN120475964A
There is provided a composition comprising: (a) an active ingredient; and (b) a lipid mixture comprising: (i) a cationically ionizable lipid capable of forming lipid nanoparticles; (ii) a steroid; and (iii) a negatively charged amphiphile having a hydrophilic portion and a lipophilic portion; wherein the composition is a lipid nanoparticle composition and is substantially free of a polyethylene glycol conjugated lipid wherein the polyethylene glycol (PEG) moiety of the PEG conjugated lipid has at least 5 contiguous ethylene glycol repeat units.
Resumen de: MX2025006743A
The present invention pertains to a composition comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of nucleic acids in the lipid bilayer. The present invention furthermore pertains to said composition, for use in preventing and/or treating a disease, in particular for use in preventing and/or treating cancer. The present invention furthermore pertains to a method for producing a composition comprising said nucleic acid-lipids particles.
Resumen de: WO2024134220A1
The present invention provides a cup-shaped particle comprising a first polymer and a second polymer; wherein the first polymer is a biodegradable polymer; the second polymer is a crosslinked copolymer of two or more different methacrylate monomers and at least one crosslinking agent, wherein the at least one cross-linking agent comprises one or more dimethacrylates; and wherein the cup has a cavity having an opening of at least 50 nm in size.
Resumen de: MX2025007204A
Aspects of the present disclosure provides for improved mycobacterium tuberculosis vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl - dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Other aspects of the present disclosure provide mRNA that encodes for concatenated peptides encoding for multiple MHC-II tuberculosis epitopes, and optionally includes a second mRNA encoding for concatenated MHC-I tuberculosis epitopes.
Resumen de: CN120842107A
本发明提供一种化合物或其N‑氧化物、溶剂合物、药学上可接受的盐或立体异构体，还提供了包含前述化合物的组合物以及它们用于递送治疗剂或预防剂的用途。本发明丰富了阳离子脂质化合物的种类，为核酸药物、基因疫苗、小分子药物、多肽或蛋白质药物的有效递送提供更多选择。当与其它脂质成分形成脂质纳米颗粒后，能够有效地递送mRNA或药物分子到细胞内发挥生物功能。
Resumen de: MX2025004375A
The present disclosure provides compositions, systems, and methods related to cellular transduction. In particular, the present disclosure provides compositions, systems, and methods pertaining to implantable macroporous scaffolds that facilitate rapid and highly efficient cellular transduction.
Resumen de: CN120836673A
本发明公开了一种防控罗非鱼链球菌病的复合抑菌剂及制备方法和应用，复合抑菌剂包括：五倍子鞣质纳米微囊25％～30％、杜仲绿原酸‑壳聚糖复合物25％～35％、黄芩苷磷脂复合物10％～20％、枯草芽孢杆菌GS‑02代谢产物冻干粉5％～15％及酸化改性凹凸棒土余量。在饲料中添加1.5％该复合抑菌剂可显著降低链球菌病累计发病率至5.3％，增重率提高22.1％，饵料系数降至1.21，且无恩诺沙星药物残留。该复合抑菌剂适用于饲料添加、水体泼洒及缓释凝胶剂多种应用场景；特别适用于循环水养殖系统，以缓释凝胶块形式按每10m3水体200g悬挂时，可维持有效抑菌浓度30天，使链球菌累计感染率降至≤1.2％。
Resumen de: CN120837616A
本发明涉及生物医用纳米材料技术领域，具体是超声响应多功能携氧纳米粒子及其制备方法和应用。本发明针对现有骨关节炎治疗载体存在的功能单一、靶向性不足及氧利用率低等问题，通过多级自组装技术构建具有"四合一"功能的智能递送系统，即超声响应多功能携氧纳米粒子，其具有关节微环境pH响应性、软骨细胞靶向性、超声响应释氧、二氧化碳吸附的“四合一”多重功能，通过体内和体外验证了其能够在细胞外微环境超声响应下维护软骨细胞纤维透明化平衡，改善软骨细胞线粒体功能和能量代谢，延缓软骨退变的效果；其具有良好生物相容性，个性化生物学功能，满意的体内外治疗效果，拓展了功能化、个性化生物纳米材料在骨关节炎领域的应用前景。
Resumen de: CN120837497A
本发明属于生物医药技术领域，具体公开金属离子螯合剂TPEN在肺癌治疗中的应用及其联合肺癌免疫治疗制剂在治疗肿瘤中的应用。本公开一方面提供TPEN在治疗肺癌中的应用，还提供TPEN用于增强肺癌免疫治疗疗效的应用，进一步提供TPEN联合肺癌免疫治疗制剂在制备治疗肺癌产品中的应用。本公开中，验证了“铜/锌金属离子螯合‑泛凋亡激活‑免疫微环境重塑”级联反应介导的“肿瘤细胞直接清除”和“抗肿瘤免疫激活”双重作用，并显著抑制原发肿瘤生长，确立的“金属离子螯合驱动泛凋亡”作为一种变革性治疗策略，解决了传统免疫治疗的局限性，并为NSCLC治疗提供了一种有前途的方法。
Resumen de: CN120837448A
本发明提供了一种靶向肿瘤的光控化学生成过氧亚硝酸根的纳米产生器及其制备方法和应用，靶向肿瘤的光控化学生成过氧亚硝酸根的纳米产生器包括内核以及包覆所述内核的包覆层，所述内核包括负载BNN‑6的普鲁士蓝，所述包覆层包括肿瘤细胞膜。本发明能够实现近红外I区光照射下对肿瘤细胞的特异性产生ONOO‑，抑制丙酮酸激酶（PK）和谷氨酰胺酶（GLS）的活性，破坏肿瘤细胞的糖酵解和谷氨酰胺代谢。
Resumen de: CN120837609A
本发明公开了一种用于治疗牙周炎的金属多酚蛋白质药物无创透膜递送系统，制备方法如下：S1、以香叶酸和碳酸氢胆碱为原料制备离子液体；S2、首先，将表没食子儿茶素‑3‑没食子酸酯(EGCG)溶于Milli‑Q超纯水，搅拌至完全溶解，逐滴加入FeCl3溶液，避光搅拌30‑60min，得到蓝黑色溶液；然后，将PDGF‑BB冻干粉加入蓝黑色溶液中，冰浴静置10‑20min，然后冰浴下超声处理数分钟，冷冻干燥，得到金属‑多酚网络包裹的PDGF‑BB，即为Fe3+@EGCG‑PDGF‑BB纳米粒子；S3、将Fe3+@EGCG‑PDGF‑BB纳米粒子加入步骤S1的离子液体中，超声处理数分钟，得到目标物Fe3+@EGCG‑PDGF‑BBIL。本发明首次将离子液体作为多酚‑蛋白质类药物(PDGF‑BB)纳米粒子的递送载体，得到了高效、安全的蛋白质类药物透牙龈无创治疗牙周炎的全新药物递送系统。
Resumen de: CN120837525A
本发明公开了一种钼基ZIF‑67抗菌纳米粒及其制备方法与应用，属于纳米药物技术领域。本发明在40‑65℃下，将四水合钼酸铵分散液加入六水合硝酸钴分散液中，得到含有钼和钴的有机配体溶液；将其加入聚乙烯吡咯烷酮的2‑甲基咪唑分散液中，在0～5℃下静置，加入三乙胺，搅拌反应得到初始反应溶液，进一步在超声作用下反应得到Mo/ZIF‑67溶液，固液分离，洗涤沉淀，过滤，干燥制得钼基ZIF‑67抗菌纳米粒。本发明制备方法实现了钼基ZIF‑67的高效、可控合成，获得结晶度良好、粒径均匀，抗菌效果明显的钼基ZIF‑67抗菌纳米粒材料。
Resumen de: CN120837451A
本发明涉及核酸药物制剂技术领域，公开了一种基于积雪草酸的脂质纳米颗粒及其制备方法与应用，该脂质纳米颗粒由摩尔比为10‑85：20‑60：1‑30：0.1‑10：0.1‑50的可电离的阳离子脂质、结构脂质、中性脂质、PEG脂质和积雪草酸组成以作为核酸药物的递送载体，用于递送核酸药物。本发明创新性地采用天然产物积雪草酸部分替代传统LNP配方中的结构脂质（如胆固醇），显著优化了其微观形态，从而大幅增强了mRNA在体内外的转染与表达效率。基于该载体构建的mRNA疫苗可诱导机体产生高滴度的特异性抗体，显著增强细胞毒性T淋巴细胞（CTL）杀伤活性。该LNP系统在肿瘤免疫预防与治疗领域表现突出，展现出优越的转化应用潜力和广阔的市场前景。
Resumen de: CN120837450A
本发明涉及一种脂质纳米颗粒制剂，具体涉及包含脂质体和荷载的脂质纳米颗粒，所述脂质体包括靶向功能脂质和脂质载体组分。本发明还涉及所述脂质纳米颗粒制剂在治疗或预防与动脉粥样硬化相关的疾病的药物中的用途。
Resumen de: CN120842103A
本发明公开了含氮链状化合物、制备方法、包含其的组合物和应用。本发明具体公开了一种化合物I或其药学上可接受的盐。采用本发明的含氮链状化合物制备得到的LNP制剂，纳米颗粒大小相对均匀，包封率较高，体内表达活性较高。
Resumen de: CN120837661A
本发明公开了一种双磷酸盐和腺嘌呤核苷三磷酸协同修饰的磷酸钙纳米颗粒及其制备方法和应用，属于生物医药技术领域，包括以下步骤：将氯化钙溶液、Tris缓冲液溶于水中，得到第一溶液；将含磷酸氢二钠的HEPES 缓冲液加入水中，再加入双磷酸盐、腺嘌呤核苷三磷酸，搅拌均匀，得到第二溶液；将第二溶液滴入第一溶液中，搅拌均匀，得到混合液，将混合液离心，洗涤，干燥，得到双磷酸盐和腺嘌呤核苷三磷酸协同修饰的磷酸钙纳米颗粒；本发明通过双磷酸盐、腺嘌呤核苷三磷酸的协同作用，改善磷酸钙纳米颗粒的尺寸，并调整其Zeta电位，从而提高其在体内的循环时间及递送效率和稳定性，提高了核酸疫苗的递送效率，进而增强疫苗的免疫效果。
Resumen de: CN120456928A
Described herein are compounds comprising lipids attached to a polymer backbone having functional groups. Also described herein are uses of such agents for delivering nucleic acids to cells.
Resumen de: CN120077061A
The technology disclosed and described herein relates to multimode mRNA-based immunotherapy that delivers both antigens and immunomodulators. Related formulations, methods of administration, and kits are disclosed and described.
Resumen de: CN120187434A
The present invention relates to compounds for use in methods for treating patients suffering from conditions associated with bacterial or fungal severe sepsis and bacterial or fungal septic shock and conditions resulting therefrom, pharmaceutical compositions containing said compounds and their use as medicaments for the treatment of bacterial or fungal severe sepsis and bacterial or fungal septic shock and the conditions resulting therefrom. # imgabs0 #
Resumen de: US2025242049A1
It is an object of the present invention to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem/progenitor cell or mesenchymal stem cells, and a method of delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule, wherein the lipid nanoparticle comprises an ionizable lipid, and the targeting molecule specifically binds to a marker of hematopoietic stem/progenitor cells or mesenchymal stem cells.
Resumen de: AU2025203403A1
0324 The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
Resumen de: CN120837449A
本发明属于生物制药领域，具体涉及一种具有内质网靶向的抗氧化功能纳米酶及其制备方法和应用。本发明所提供的新型抗氧化纳米酶(Arg‑Mnzyme)，能有效抑制NOX1的表达消除活性氧的积累，抑制颞下颌关节炎性疼痛后NOX1的激活和氧化应激的发生，发挥了减轻疼痛超敏反应的作用。相比于天然酶而言，纳米酶具有更强的修饰性，本发明将构建一种内质网精准抗氧化纳米酶将实现氧化应激的精准调控。
Nº publicación: JP2025162553A 27/10/2025
Solicitante:
マイエロイド・セラピューティクス，インコーポレーテッド
Resumen de: GB2626698A
A pharmaceutical composition comprising: (a) a recombinant nucleic acid, wherein the recombinant nucleic acid comprises a sequence encoding a chimeric fusion protein (CFP), the CFP comprising: an extracellular domain comprising an anti-GPC3 binding domain, a transmembrane domain of FcRα or FcRβ operatively linked to the extracellular domain; an intracellular domain comprising one or more intracellular signaling domains; and(b) a pharmaceutically acceptable carrier; wherein the CFP forms a functional complex with FcRγ in myeloid cells.
BOPI
Sede Electrónica
